After repeated chemotherapy sessions, many patients feel the repercussions and pain. But beyond the pain is the loss of quality of life. Dr. Ross Camidge, Director of Thoracic Oncology at the University of Colorado Cancer Center, navigates us through one unforgettable case of a patient with NSCLC, which holds an unexpected lesson for all physicians

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Dr. Ross Camidge from the University of Colorado discusses the concepts to consider and his own personal rationales behind implementing aggressive disease management for patients with NSCLC.

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

At the very least, any successful non-small cell lung cancer (NSCLC) care team needs to include a medical oncologist, pulmonologist, pathologist, radiologist, and even a molecular pathologist. Reviewing the value of each of these roles in tackling NSCLC is Dr. Edward Kim, Chair of Solid Tumor Oncology and Investigational Therapeutics at Levine Cancer Institute.

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

What’s the best course of action for those patients with non-small cell lung cancer (NSCLC) that’s rapidly growing? Join Dr. Edward Kim, Chair of Solid Tumor Oncology and Investigational Therapeutics at Levine Cancer Institute, as he reviews some of the methods that aim to achieve the best response rate in these patients.

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

For those non-small cell lung cancer (NSCLC) patients without driver mutations or PD-L expressions, the new care paradigm brought on by KEYNOTE-189 has shown to improve these patients’ progression-free survival rates. Here to break down this clinical trial’s unprecedented findings is Dr. Edward Kim, Chair of Solid Tumor Oncology and Investigational Therapeutics at Levine Cancer Institute.

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Obtaining a tissue biopsy has always been the standard for reaching both early and late-stage non-small cell lung cancer (NSCLC) diagnoses, but that’s no longer the case for all stages. See for yourself how the paradigm has changed with Dr. Edward Kim, Chair of Solid Tumor Oncology and Investigational Therapeutics at Levine Cancer Institute.

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Dr. Benjamin Weinberg, assistant professor at Georgetown University, examines the determinants of disease progression of metastatic colorectal cancer and how these can lead to better approaches to tailored care and personalized management of your patients.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Keeping up with rapid advancements in mCRC, the NCCN updated their guidelines to encompass the perplexity of tumor sidedness. Dr. Benjamin Weinberg, Assistant Professor at Georgetown University, interprets the distinctions between right versus left-sided tumor sites and how these developments could impact your treatment selection for patients.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

The NCCN guidelines are the foundation of clinical practice, supporting the decisions of all in the oncology community. For this reason, advancements in the therapeutic landscape of metastatic colorectal cancer have led to necessary adaptations of the guidelines. Reflecting on these influential modifications is Dr. Benjamin Weinberg, Assistant Professor at Georgetown University.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Over the years, tumor sidedness has become an area of immense interest for the oncology community. And while they have shown inferior outcomes for patients with the primary site on the right side versus the left, questions still remain as to why. Dr. Benjamin Weinberg, an Assistant Professor at Georgetown University, details why sidedness may be a prominent prognostic indicator.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.